IL-6 is involved in the formation and destabilization of atherosclerotic plaques
with C-terminal 8* His LEVPNGPWRSLTFYPAWLTVSEGANATFTCSLSNWSEDLMLNWNRLSPSNQTEKQAAFCNGLSQPVQDARFQIIQLPNRHDFHMNILDTRRNDSGIYLCGAISLHPKAKIEESPGAELVVTERILETSTRYPSPSPKPEGRFQGGGSHHHHHHHH
Cancer/testis (CT) antigens including MAGEA
application dilution species IHC-P 1:1000 WB 1:500 IP 1:25 ICC 1:250 IF 1:500 ChIP 1:20-1:50
with C-terminal 8*His DTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPNVYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAATWSHHHHHHHH Expression System HEK293 Molecular Weight 45-56 kDa(Reducing) Purity >95% by SDS-PAGE
CD31 Recombinant Rabbit mAb (SDT-008-17) Size:25μl IL-6 is involved in theProduct Specification Host Rabbit Antigen CD31 Synonyms PECAM 1,EndoCAM, GPIIA, PECA1 Immunogen Synthetic Peptide Accession P16284 Clone Number SDT 008 17 Antibody Type Rabbit mAb Isotype IgG Application WB, IHC P, IP Reactivity Hu Purification Protein A Research Area Immunology Concentration 0. 5mg ml Molecular Weight 150kDa Conjugation Unconjugated Physical Appearance Liquid Storage Buffer PBS, 40% Glycerol, 0. 05%BSA, 0. 03% Proclin 300 Stability &